Population
Women with metastatic breast cancer receiving doxorubicin-containing therapy
Comparison
Dexrazoxane (DZR) vs Placebo
Design
Editorial
Authors
Loading...
The authors reaffirm the ASCO guideline recommendation to consider dexrazoxane for metastatic breast cancer patients who have received ≥300 mg/m2 of doxorubicin and need continued therapy, despite concerns about hematologic toxicity and response rates.
The authors reaffirm the ASCO guideline recommendation to consider dexrazoxane for metastatic breast cancer patients who have received ≥300 mg/m2 of doxorubicin and need continued therapy, despite concerns about hematologic toxicity and response rates.
Hellmann et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: